Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lucentis was produced by Novartis and Roche.

Regeneron’s Dupixent and Praluent falls short

Regeneron’s Dupixent and Praluent falls short momentum. Eylea is already fending off pressure from Novartis’ Lucentis (ranibizumab) but faces more competition in the market from late-stage experimental drugs such as Novartis’ RTH258, as well as biosimilars ... of Lucentis.

The good, the bad and the ugly

The good, the bad and the ugly It hopes these measures will help offset Lucentis’ EU patent expiry in 2022.”. ... Regeneron remains the leading player, with 10% growth in 2017 thanks to superior data for Eylea against Lucentis.

It’s only money

It’s only money problem breached European Union competition rules - this ruling upheld a 2014 decision by Italy’s antitrust authority that the drugmakers colluded to boost sales of Lucentis by discrediting the cheaper Avastin

Regeneron and Bayer drop AMD combination

Regeneron and Bayer drop AMD combination Novartis does have to be wary of cannibalising sales of its established AMD therapy Lucentis (ranibizumab), which is playing second fiddle to Eylea but is still a blockbuster – albeit one headed

NICE first fast-track appraisal backs Bayer's Eylea

NICE first fast-track appraisal backs Bayer's Eylea will compete against Novartis’ already NICE-recommended Lucentis ( ranibizumab).

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts


Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...